Eli Lilly and Company announced a significant expansion at its Pleasant Prairie facility Thursday. The pharmaceutical giant plans a $3 billion investment, which is expected to create 750 new jobs at ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it ...
Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines. The drugmaker said the Kenosha County, ...
Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial.
(Reuters) - Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant ...
Data suggests that dramatic weight loss, including via GLP-1 drugs, could save Americans big bucks in healthcare spending.
Airlines don't always honor requests to protect the health of people with food allergies during flights, a new study found.
Lilly’s blockbuster weight-loss and diabetes drugs have made it the most valuable pharmaceutical company in the world.
The initial rollout of Eli Lilly's weight loss drug Zepbound in the UK will first go to those with the great clinical need ...
Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a ...
Key Takeaways Patients taking Eli Lilly's Zepbound lost more weight on average than those on Novo Nordisk's Wegovy in a new ...